TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with non-resectable, histologically confirmed, synchronous or metachronous colorectal liver metastases. Patients with non-resectable metastases are defined as; patients with five or more liver metastases; and/or patients with liver metastases that are technically non-resectable (local surgeon in cooperation with local radiologist will define non-resectability on the basis of remaining functional liver tissue, infiltration of all liver veins, infiltration of both liver arteries, both portal branches or both bile ducts).~* Patients with simultaneous liver metastases are eligible, if the primary tumor has been resected at least 1 month prior to chemotherapy.~* Karnofsky Performance Status ≥ 80~* Informed consent~* Adequate bone marrow function, liver and renal function (neutrophils \> 1.5 x 10\^9/l; thrombocytes \> 100 x 10\^9/l; hemoglobin \> 8.0 g/l; bilirubin ≤ 1.5 x upper limit of normal \[ULN\] and not increasing more than 25% within the last 4 weeks; ALAT and ASAT \< 5 x UNL; serum creatinine ≤ 1.5 x UNL)~* Age ≥ 18 years~Exclusion Criteria:~* Any evidence of extrahepatic metastases, lymph node metastases and primary tumor recurrence~* Prior chemotherapy (except adjuvant chemotherapy with an interval of ≥ 6 months)~* Previous exposure to EGFR (epidermal growth factor receptor)-targeting therapy~* Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic biopsy or port implantation) ≤ 4 weeks before study entry~* Concurrent systemic immune therapy, chemotherapy, or hormone therapy~* Investigational agents or participation in clinical trials within 30 days before start of the treatment in study~* Clinically relevant coronary disease or myocardial infarction within 12 months before study entry~* Peripheral neuropathy \> CTC grade I~* Inflammatory bowel disease~* Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)~* History of severe psychiatric illness~* Drug or alcohol abuse~* Breast feeding or pregnant women, no effective contraception if risk of conception exists (male and female patients)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Cetuximab and FOLFIRI
- 2 (Type: ACTIVE_COMPARATOR): Cetuximab and FOLFOX

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Veteran Stress and Learning Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans and civilians with an age range of 18 to 65 years~* Participants must be physically healthy volunteers~Exclusion Criteria:~* Individuals who fall outside the age range~* Individuals with medical conditions that would interfere with participation~* Other criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1: Hydrocortisone (Type: EXPERIMENTAL): Hydrocortisone
- Arm 2: D-Cycloserine (Type: EXPERIMENTAL): D-Cycloserine
- Arm 3: Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women ≥18 years of age~* Subjects with Type Type 2 Diabetes Mellitus as defined by the American Diabetes Association~* Diagnosis of Diabetic Kidney Disease with persistent high albuminuria or persistent very high albuminuria at the Run-In and Screening Visit~* Pretreated with either angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at maximal tolerated labeled dose without adjustments~* Serum potassium \<=4.8 mmol/L~Exclusion Criteria:~* Confirmed significant non-diabetic renal disease, including clinically relevant renal artery stenosis~* Uncontrolled arterial hypertension (ie, mean sitting systolic blood pressure (SBP) ≥170 mmHg or mean sitting diastolic blood pressure(DBP) ≥110 mmHg at run in visit, or mean sitting SBP ≥160 mmHg or mean sitting DBP ≥100 mmHg at screening)~* Clinical diagnosis of chronic heart failure with reduced ejection fraction (HFrEF) and persistent symptoms {New York Heart Association (NYHA) class II - IV} at Run in visit \[class 1A recommendation for mineralcorticoid receptor antagonist (MRAs)\]~* Dialysis for acute renal failure within 12 weeks of Run-in visit~* Renal allograft in place or scheduled kidney transplant within next 12 months~* Glycated hemoglobin (HbA1c) \>12%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BAY94-8862 (Type: EXPERIMENTAL): Finerenone tablet
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 19 years and older, younger than 70 years old~* American society of Anesthesiologists physical status classification I to III~* those who undergo laparoscopic gynecologic, abdominal or other surgery under general anesthesia~* surgery for which anesthesia is expected to last at least 30 minutes~* if a subject has or may develop prolongation of cardiac conduction intervals, particularly corrected QT interval, he/she may be enrolled at the discretion of the investigator.~Exclusion Criteria:~* known hypersensitivity/ contraindication to 5-hydroxytryptamine antagonists or study drug excipient~* inability to understand or cooperate with the study procedures as determined by the investigator~* women who are pregnant, nursing or planning to become pregnant, are not using effective birth control, or that have had a positive serum pregnancy test within 7 days prior to surgery day 1.~* has received any investigational drug within 30 days before study entry~* having taken any drug with potential antiemetic efficacy within 24 hour prior to anesthetic procedures.~* any vomiting, retching, or nausea in the 24 hours preceding the administration of anesthesia~* known or suspected current history of alcohol abuse or drug abuse.~* any condition, which in the opinion of the investigator would make the subject ineligible for participation in the study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Palonsetron (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* \>= 18 years of age~* Stage IIIc or Stage IV BRAF V600E/K cutaneous melanoma~* Measurable disease according to RECIST 1.1~* Women of childbearing potential with negative serum pregnancy test prior to randomisation~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1~* Adequate baseline organ function~Key Exclusion Criteria:~* Any prior use of a BRAF or MEK inhibitor~* Prior systemic anti-cancer treatment in the advanced or metastatic setting; prior systemic treatment in the adjuvant setting is allowed~* History of another malignancy (except subjects who have been disease free for 3 years or with a history of completely resected non-melanoma skin cancer)~* Known HIV, HBV, HCV infection (except chronic or cleared HBV and HCV infection which will be allowed)~* Brain metastases (except if all known lesions were previously treated with surgery or stereotactic radiosurgery and lesions, if still present, are confirmed stable for \>= 12 weeks prior to randomisation or if no longer present are confirmed no evidence of disease for \>= 12 weeks, and are asymptomatic with no corticosteroid requirements for \>= 4 weeks prior to randomisation, and no enzyme inducing anticonvulsants for \>= 4 weeks prior to randomisation~* History or evidence of cardiovascular risk (LVEF \< LLN; QTcB \>= 480 msec; blood pressure or systolic \>=140 mmHg or diastolic \>= 90 mmHg which cannot be controlled by anti-hypertensive therapy)~* History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabrafenib plus Trametinib (Type: EXPERIMENTAL): BRAF inhibitor plus MEK inhibitor
- Vemurafenib (Type: ACTIVE_COMPARATOR): BRAF inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory postmenopausal Korean women, ≥ 55 to ≤ 90 years of age at enrollment.~* Postmenopause is defined as no spontaneous vaginal bleeding or spotting for 12 or more consecutive months prior to screening.~* BMD T-score \</= -2.50 at the lumbar spine, total hip or femoral neck.~* At least 2 vertebrae in the L1 through L4 region and at least one hip are evaluable by DXA.~* Other inclusion criteria may apply.~Exclusion Criteria:~* Subjects with a BMD T-score \</= -4.0 at the lumbar spine, total hip, or femoral neck.~* History of hip fracture.~* Bone disease other than osteoporosis/ or evidence of any other clinically significant disorder, condition/ or disease or significant laboratory abnormalities.~* Known sensitivity or intolerance calcium and vitamin D products.~* Other exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once a month for 6 months.
- Romosozumab (Type: EXPERIMENTAL): Participants received 210 mg romosozumab by subcutaneous injection once a month for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers selected by ANRS (French National Agency for Research on AIDS and Viral Hepatitis)~* For woman of child-bearing age: use of effective contraception~* Ability to sign informed consent~* Beneficiary subjects of social security regimen-- Hepatitis B, hepatitis C, HIV, HTLV1 infection and syphilis negative~* Hemoglobin over 12.5 g/dl for women and over 13.5 g/dl for men~Exclusion Criteria:~* Previous participation in an HIV clinical trial~* Volunteers with risk to contract HIV infection during the trial~* Previous vaccination in the last month, and volunteers requiring vaccination during the trial~* Gift of blood in the last 2 months~* Eczema, urticaria~* Medical history of food allergy, Lyell or Stevens Johnson syndrome and aggravated asthma~* Previous (last 6 months) or ongoing administration of immunological treatment, chemotherapy, radiotherapy or corticosteroid~* Medical history of autoimmune disease~* Clinical or biological aftermath of previous disease~* Medical history of uveitis~* Transfusion in the last 6 months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapy of Early Chronic Phase CML With Gleevec

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Philadelphia chromosome (Ph)- positive or breakpoint cluster region (bcr)-positive CML in early chronic (diagnosis \< 12 months).~2. Age 15 years or above~3. Adequate renal, hepatic, cardiac and performance status (ECOG 0-2) - no psychiatric disability (psychosis)~4. Signed informed consent~Exclusion Criteria:~1. Grade 3-4 cardiac~2. Psychiatric problem~3. Pregnant or lactating

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gleevec (Type: EXPERIMENTAL): Gleevec 400 mg orally daily. Dose adjustments made at discretion of treating physician within these guidelines: The highest dose acceptable is 800 mg daily. The lowest dose acceptable is 300 mg. No dose adjustment of more than 200 mg at one time is allowed. Dose adjustments to less than 300 mg may be approved after consultation with the principal investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria at the time of the randomization:~* Must have a confirmed diagnosis of RRMS according to McDonald criteria #1-4.~* Must have a baseline EDSS between 0.0 and 5.0, inclusive.~* Must have relapsing-remitting disease course.~Key Exclusion Criteria:~* Unless otherwise specified, candidates will be excluded from study entry if any of the following exclusion criteria exist at randomization:~* Other chronic disease of the immune system, malignancies, acute urologic, pulmonary, gastrointestinal disease.~* Pregnant or nursing women.~Note: Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received two placebo capsules orally three times daily (TID)
- BG00012 240 mg Twice Daily (BID) (Type: EXPERIMENTAL): Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
- BG00012 240 mg 3 Times Daily (TID) (Type: EXPERIMENTAL): Participants received two 120 mg BG00012 capsules orally three times daily (TID)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent for participation before the completion of MT-3995-J05 Study~* Completion of MT-3995-J05 study~Exclusion Criteria:~* UACR of ≥300 mg/g Cr with an increase of ≥30% in MT-3995-J05 Study~* Symptomatic and clinically significant hypotension~* QT prolongation or torsades de pointes~* New York Heart Association (NYHA) Class III or IV heart failure~* Patients who are judged to be unsuitable for participation based on their safety profile in MT-3995-J05 Study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MT-3995 Low (Type: EXPERIMENTAL): None
- MT-3995 Middle (Type: EXPERIMENTAL): None
- MT-3995 High (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The BrainHealth Project - Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Minimum age of 18~* internet access and device~* fluent English speaker~Exclusion Criteria:~* Children are excluded from this study~* Individuals who do not speak or read English~* If individuals have undergone an in-person BrainHealth Index (previously BrainHealth Physical), they will need to wait 6 months have passed to participate.~* Individuals who will complete the imaging component must pass an fMRI screener and score a 26 or above on the TICS (Telephone Interview Cognitive Status)-M.~* A history of neurological disorders, injuries or disabilities (dementia, multiple sclerosis, Parkinson's, traumatic brain injury, stroke)~* A history of psychiatric disorders (schizophrenia, bipolar disorder, or others related to anxiety, depression, panic)~* A history of uncontrolled health issues (substance abuse, hypertension, hypo- or hyper-thyroidism)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Online SMART Intervention & Stress Solutions (Type: EXPERIMENTAL): Strategic Memory Advanced Reasoning Training (SMART) teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 18-50 years of age who:~* are in good health at the time of entry into the study as determined by medical history, physical examination and clinical judgment of the investigator;~* volunteer for the simulated post-exposure vaccination courses and blood draws;~* have given a written informed consent; informed consent must be obtained for all the subjects before enrolment in the study;~* are available for all the visits scheduled in the study.~Exclusion Criteria:~* Subjects with the below criteria were excluded:~* pregnancy or unwillingness to practice acceptable contraception during participation in the study;~* a history of rabies immunization;~* a significant acute or chronic infectious disease that may impact the subject's safety and /or immunogenicity in the Investigators opinion at the time of enrolment;~* fever ≥ 38.0°C (axillary) or/and significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrolment;~* treatment with corticosteroids, immunosuppressive or antimalaria drugs during the two month period before enrolment;~* administration of any vaccine within the past 14 days before enrolment;~* known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder;~* history of allergy to egg protein;~* known hypersensitivity to neomycin, tetracycline, amphotericin-B, or any other vaccine component;~* treatment with parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months;~* mental condition rendering the subject unable to understand the nature, scope and consequences of the study;~* participation in any other investigational trial within the past 3 months before enrolment;~* planned surgery during the study period;~* intention to leave the area of the study site before the end of study period;~* any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objective.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Zagreb (2-1-1) (Type: EXPERIMENTAL): Rabies PCEC vaccine was applied according Zagreb schedule with 2 vaccinations on day 0, 1 vaccination on day 7 and day 21, respectively
- Essen (1-1-1-1-1) (Type: ACTIVE_COMPARATOR): Rabies PCEC vaccine was applied according Essen schedule, i.e. 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete